^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Adjuvant pembrolizumab in genomically selected high-risk patients with muscle-invasive bladder cancer

Published date:
05/20/2021
Excerpt:
...case series of two patients who received cisplatin-based neoadjuvant chemotherapy and had pathologic node-positive urothelial carcinoma at the time of radical cystectomy. Tumor next generation sequencing revealed high mutational burden in both patients and positive PD-L1 in one patient....Management and outcome: Patients were treated with adjuvant pembrolizumab and experienced long-term disease free intervals.
DOI:
https://doi.org/10.1177/10781552211016526